The maturation status of dendritic cells (DCs) determines whether they prime or tolerize T cells. We targeted ovalbumin peptide exclusively to DCs in situ using an antibody to DEC-205 and studied the interaction of DCs with naive CD4 + T cells in tolerizing or priming conditions. We used two-photon microscopy to simultaneously track antigen-specific OT-II T cells, nonspecific T cells and DCs in lymph nodes of living mice. In both tolerance and immunity, OT-II cells arrested on DCs near high endothelial venules beginning shortly after extravasation and regained their baseline speed by 18 h. Thus, early antigen-dependent T cell arrest on DCs is a shared feature of tolerance and priming associated with activation and proliferation.
The maturation status of dendritic cells (DCs) determines whether they prime or tolerize T cells. We targeted ovalbumin peptide exclusively to DCs in situ using an antibody to DEC-205 and studied the interaction of DCs with naive CD4 + T cells in tolerizing or priming conditions. We used two-photon microscopy to simultaneously track antigen-specific OT-II T cells, nonspecific T cells and DCs in lymph nodes of living mice. In both tolerance and immunity, OT-II cells arrested on DCs near high endothelial venules beginning shortly after extravasation and regained their baseline speed by 18 h. Thus, early antigen-dependent T cell arrest on DCs is a shared feature of tolerance and priming associated with activation and proliferation.
Laser-scanning microscopy allows imaging of live cells at depths of up to 300 mm in lymph nodes removed from mice (explanted) [1] [2] [3] [4] [5] [6] or exposed surgically in anesthetized mice (intravital) [7] [8] [9] . Both kinds of preparations have been used to study mature dendritic cells (DCs) actively participating in immune responses 1, [3] [4] [5] 7 , but lymph nodes imaged by intravital microscopy differ from those of explanted preparations in that they have preserved blood and lymph flow.
Mature DCs have been visualized by labeling with exogenous fluorescent dyes and have been found to crawl slowly in random directions, rapidly extending and retracting long dendritic processes 1, [3] [4] [5] 7 . The activity of steady-state DCs in live anesthetized mice has been examined by intravital two-photon microscopy in transgenic mice with high expression of enhanced yellow fluorescent protein (EYFP) in CD11c + DCs (CD11c-EYFP mice) 10 . DCs in these mice are indistinguishable from DCs of wild-type mice, based on immunohistochemistry and flow cytometry. In the steady state, DCs actively probe passing T cells with dendritic processes, but show little translational movement and are present in extensive interdigitating networks in the T cell zones. These DC networks are present throughout the T cell area, including areas around high endothelial venules (HEVs), such that T cells exiting HEVs would rapidly encounter the DC network. In addition, transferred mature DCs demonstrate 'translational' movement as they disperse throughout the networks of endogenous DCs 10 .
The outcome of antigen presentation by DCs depends on the state of DC differentiation or maturation [11] [12] [13] [14] [15] [16] . In the steady state, immature DCs capture, process and present to T cells a variety of self and environmental antigens, including proteins from serum, commensal microbes and dead cells [17] [18] [19] [20] [21] [22] . The presentation of agonistic peptides on major histocompatibility complex (MHC) molecules by steady-state DCs tolerizes T cells and prevents autoreactivity when the same antigens are subsequently presented in immunizing conditions 16, [23] [24] [25] [26] [27] . In contrast, DCs activated to mature by inflammatory stimuli, including infection, Toll-like receptor ligands and CD40 ligation, induce strong effector T cell responses to the same antigens [11] [12] [13] [14] [15] [16] 23, 24, [28] [29] [30] .
Intravital two-photon microscopy has been used to image T cell priming in lymph nodes 7 and has shown that T cells interact with fully mature, antigen-loaded DCs in three phases. For the first 8 h, T cells transiently contact DCs; between 8 and 20 h, they establish stable contacts; and finally, they resume dynamic movement. In contrast, when tolerance was examined in explanted lymph nodes 6 , T cells did not establish prolonged contacts with antigen-loaded DCs. These differences in early T cell migration suggest that the stability of T cell-DC interactions determines commitment to tolerance or immunity 6 . However, nonspecific control T cells were not simultaneously visualized, and experiments based on classical immunological methods have indicated that the early stages of T cell-DC interactions are similar in tolerance and priming 23, 24, 27, 31, 32 and do not commit T cells to either 33 .
To examine tolerance and immunity in live mice, we developed a method to visualize the interaction of endogenous DCs with antigenspecific and nonspecific CD4 + T cells in the same imaging volumes. This protocol allowed us to control for the variability in T cell movement in different subcompartments of the lymph node. Here we report a previously unknown antigen-specific stop signal that acts within an hour of the entry of T cells into the lymph node through HEVs in both immunity and tolerance.
RESULTS

Antigen delivery by antibody to DEC-205
We sought to determine how widely divergent endpoints of tolerance and immunity relate to the physical interaction between DCs and CD4 + T cells during early stages of antigen recognition. To deliver antigen to DCs in vivo, we injected mice with a recombinant monoclonal antibody to the DC-specific scavenging receptor DEC-205, engineered 23 to carry an in-frame C-terminal peptide (amino acids 323-339) of ovalbumin (a-DEC-OVA). CD4 + OT-II T cells recognize this peptide when it is presented by I-A b (ref. 34) . To compare the conditions of tolerance versus priming, we used antibody to CD40 (a-CD40) as an adjuvant. This antibody is the only single-component adjuvant that we have examined that induces long-lived effector T cells with a single injection 30 . It induced upregulation of CD80, CD86 and MHC class II on lymph node CD11c + DCs between 6 and 12 h after injection ( Supplementary Fig. 1 online) . Accordingly, we timed the injection of a-CD40 so that upregulation of CD80, CD86 and MHC class II were maximal in the time frame of our imaging experiments.
In the steady state (without a-CD40), OT-II cells responded to a-DEC-OVA by upregulating CD69 and downregulating CD62L surface expression within 3 h of exposure to antigen (Fig. 1a) . By day 3 there was extensive T cell division, but most of the responding cells were deleted by day 7 (Fig. 1b,c) . Whereas OT-II cells reisolated after 3 d remained antigen responsive, the few OT-II cells remaining after 7 d were unresponsive to restimulation in vitro and therefore were tolerant (Fig. 1d) . When a-CD40 was given in conjunction with a-DEC-OVA, there was similar expression of CD69 and CD62L and similar amounts of OT-II cell division were present at day 3 (Fig. 1a) . However, OT-II cells responding to antigen in the presence of a-CD40 adjuvant persisted at day 7 and showed enhanced proliferation in response to antigen in vitro, indicating T cell priming (Fig. 1b-d) . Thus, antigen presentation by DCs targeted with a-DEC-OVA resembles the previously described a-DEC-targeted antigens in that the outcome of antigen presentation in the steady state differs substantially from presentation of the same antigen in immunizing conditions 23, 24, 27, 30 . Therefore, despite the difference in outcome, T cells responding to antigen presented by DCs in tolerizing and immunizing conditions are initially (at day 3) indistinguishable in terms of cell surface activation antigen expression and the ability to respond to antigen in vitro.
T cell retention around HEVs
To determine whether T cells were differentially distributed in lymph nodes in conditions of tolerance and immunity, we studied antigenspecific T cells (CD4 + OT-II) and nonspecific T cells (naive non-TCRtransgenic CD4 + ), both expressing enhanced green fluorescent protein (EGFP), and examined their fates in lymph nodes at 3 or 24 h after exposure to antigen. At 3 h after transfer, antigen-specific T cells were present in close proximity to HEVs (average distance, 59 mm), and only 13% were in the deep paracortex (Fig. 2) . In contrast, the nonspecific T cells were an average of 78 mm from HEVs (P o 0.0001) and were more evenly distributed throughout the T cell area, with 32% in the deep paracortex. By 24 h, both antigen-specific and nonspecific cells were uniformly distributed throughout the T cell area, with 43-45% present in the deep paracortex, and were located on average 90 mm from the center of the nearest HEV (Fig. 2) . CD40 ligation did not alter the distribution of either the antigen-specific or nonspecific T cells at either time point (Fig. 2) . Similar experiments simultaneously visualizing OT-II cells expressing enhanced cyan fluorescent protein (ECFP) and nonspecific T cells expressing EGFP produced identical results (data not shown). We conclude that T cells that recognize a specific antigen are restricted to the area around HEVs in the early phases of tolerogenic and immunogenic responses.
Visualizing DCs and T cells in live mice
To visualize interactions between DCs and T cells, we injected CD11c-EYFP mice 10 with a-DEC-OVA with or without a-CD40 (Supplementary Fig. 2 online) ; 5 h later, we adoptively transferred about 1 Â 10 7 antigen-specific, EGFP-expressing, OT-II cells
(EGFP-OT-II T cells) and an equal number of naive, control, non-TCR-transgenic, CD4 + , ECFP-expressing T cells (ECFP-T cells).
In some experiments, we identified blood vessels by injection of 'Q-dots' ('quantum dots' coated with polyethylene glycol; Supplementary Video 1 online). We simultaneously imaged all fluorescent cell types in anesthetized mice at multiple depths (10-200 mm), including the outer paracortex near HEVs to the deep paracortical T cell zones, up to 18 h after T cell transfer (Fig. 3) . T cells extravasated in the first hour after injection, and we noted few extravasation events during the imaging period (Supplementary Video 2 online). Although depth has been described as a critical determinant of T cell motility 7, 35 , we found little correlation between depth and cell speed ( Supplementary  Fig. 3 online). EYFP + DCs present in the imaging fields sensitively indicated the viability of the preparation. By simultaneously visualizing OVA-specific EGFP-OT-II T cells, nonspecific ECFP-T cells and EYFP-expressing DCs in each field, we were able to identify immobility caused by phototoxicity, suboptimal temperature, inadequate blood supply or surgical trauma. We excluded from analysis fields in which T cells were globally arrested and DCs stopped probing (Supplementary Video 3 online). We tracked cells in three dimensions over the course of each imaging experiment and quantified T cell motility with regard to velocity ( . A large proportion of the specific T cells were immobile (slower than 2 mm/min) in this interval (35% versus 8.7%, specific versus nonspecific T cells; P o 0.0001; Fig. 5a ) and many sessile antigen-specific cells were present just outside HEVs ( Fig. 2d and Supplementary Video 5 online). In addition to measuring immobility, we measured the arrest coefficient 6 , which is the proportion of time that a T cell is arrested (instantaneous velocity of less than 2 mm/ min). Antigen-specific T cells spent more time arrested than did control cells (47% versus 20%; P o 0.0001; Fig. 5b ). To determine the directionality of T cell movement, we measured the turning angle 7 and confinement index 6 . Consistent with their relative immobility, we found that antigen-specific T cells moved less linearly than did nonspecific cells, as evidenced by a higher turning angle (821 versus 611; P o 0.0001; Fig. 6a ) and a lower confinement index (41% versus 56%; P o 0.0001; Fig. 6b ). In the interval of 6-12 h (Supplementary Video 6 online), the specific T cells remained significantly slower than the nonspecific T cells (5.94 versus 7.46 mm/min; P o 0.0001, Fig. 4 ), but the specific T cells were moving faster than in the interval of 1-6 h (5.94 versus 4.41 mm/min; P o 0.001, Fig. 4) . Between 6 and 12 h, antigen-specific T cells were more immobile (12.2% versus 6.0%; P o 0.05, Fig. 5a ) and had larger arrest coefficients (32% versus 13%; P o 0.0001, Fig. 5b ) and a smaller confinement index (53% versus 66%; P o 0.0001, Fig. 6b ) than the nonspecific T cells. Finally, at 12-18 h (Supplementary Video 7 online), the antigen-specific T cells were still significantly slower (7.05 versus 8.83 mm/min; P o 0.0001; Fig. 4 ) and more immobile (12% versus 2.8%; P o 0.002; Fig. 5a ) and had higher arrest coefficients (32% versus 22.3%; P o 0.001; Fig. 5b ) than control T cells, but differences in the turning angle and confinement index were not significant (Fig. 6) . Two-way analysis of variance (ANOVA) showed that the speed difference between antigen-specific and nonspecific cells was significantly greater at 1-6 h than at either 6-12 or 12-18 h (P o 0.0001 for both), whereas the difference at 6-12 h was statistically indistinguishable from the difference at 12-18 h. This suggests that antigen-specific cells were regaining motility at 6-12 h. We conclude that T cells exposed to antigen in tolerizing conditions arrest near HEVs and that mobility recovers significantly by 6-12 h after antigen exposure.
To determine whether the difference in T cell speeds reflects the induction of antigen-specific tolerance or inherent differences between EGFP-OT-II T cells and ECFP-T cells, we examined the activity of EGFP-OT-II T cells in control conditions. We injected mice with an irrelevant peptide targeted to DEC-205 or with OVA peptide fused to an isotype control antibody. In both conditions, EGFP-OT-II T cells moved at around 9 mm/min, a speed comparable to the speeds of the nonspecific ECFP-T cells in mice treated with a-DEC-OVA (data not shown) and to those reported before [2] [3] [4] [5] 7, 8 . Thus, the arrest of EGFP-OT-II T cells in mice treated with a-DEC-OVA was antigen specific.
Priming in vivo
As with tolerance, immunity was associated with early antigen-specific arrest of T cells, but recovery to normal movement was somewhat slower (Fig. 4 and Supplementary Figs. 4,5 online) . In mice treated with a-DEC-OVA and a-CD40 (Supplementary Video 8 online) , specific EGFP-OT-II T cells moved significantly slower than nonspecific ECFP-T cells in the interval of 1-6-h (mean velocity, 5.20 versus 8.78 mm/min; P o 0.0001; Fig. 4) . In this interval, the specific T cells were more immobile (31% versus 9.6%; P o 0.0001; Fig. 5a ) and had a higher arrest coefficient (40% versus 21%; P o 0.0001; Fig. 5b ), a sharper turning angle (71% versus 61%; P o 0.05; Fig. 6a ) and a smaller confinement index (41% versus 49%; P o 0.02; Fig. 6b ) than nonspecific T cells. In the interval of 6-12 h (Supplementary Video 9 online), specific T cells remained slower than nonspecific cells (4.35 versus 8.05 mm/min; P o 0.0001; Fig. 4 ) and had a higher arrest coefficient (46% versus 27%; P o 0.0001; Fig. 5b ), but were no longer significantly more immobile (Fig. 5a ). They showed a smaller confinement index (40% versus 49%; P o 0.02; Fig. 6b ), but showed no significant difference in turning angle (Fig. 6a) . Finally, in the interval Figure 4 Mean cell velocities in tolerizing and priming conditions. Mice were injected with antibodies and T cells, inguinal lymph nodes were imaged and antigen-specific and nonspecific T cells were tracked as described in Figure 3 . Antigen-specific EGFP-OT-II T cells move slowly at 1-6 h in both priming (mean cell speed, 5.2 mm/min) and tolerance (mean cell speed, 4.4 mm/min), whereas nonspecific T cells maintain their normal speed of about 9 mm/min. Error bars denote s.e.m.; *, significant difference (P values in Results). Plots summarize collective data from all experiments. Fig. 5b ) than nonspecific cells, but were otherwise indistinguishable. Two-way ANOVA showed that the speed difference between antigenspecific and nonspecific cells was significantly smaller at 12-18 h than at 1-6 h (P o 0.003) and 6-12 h (P o 0.006), whereas the difference at 1-6 h was statistically indistinguishable from the difference at 6-12 h. We conclude that in conditions of immunity, specific cells arrest initially and then recover mobility significantly 12-18 h after antigen exposure. We occasionally noted discrete T cell-DC clusters forming around DCs (Supplementary Video 11 online), but T cells were not always in contact with CD11c hi DCs (Supplementary Video 12 online), perhaps because not all DEC-205 + cells have high expression of EYFP in CD11c-EYFP mice 10 .
Comparison of tolerance and priming in vivo
Tolerance and immunity were similarly characterized by an early arrest followed by restoration of mobility. We also noted this when the speed of antigen-specific T cells was normalized to that of 'in-field' nonspecific control cells ( Supplementary Fig. 5 online) . Overall, there was little evidence for perturbation of control T cells, which maintained their mobility for at least 18 h. The most revealing parameter for comparison of specific cells in conditions of tolerance and immunity was the arrest coefficient 6 , a continuous parameter reflecting the percentage of time T cells were arrested (Fig. 5b) . At 1-6 h, the arrest coefficient for specific T cells was slightly higher in conditions of tolerance than immunity (47% versus 40%; P o 0.02). In contrast, at 6-12 h, the arrest coefficient was higher in immunity (32% versus 46%; P o 0.005). Finally, at 18 h, the arrest coefficients were uniform (32% versus 35%; not significant). Over the entire period of 1-18 h, the average arrest coefficient for antigen-specific cells was similar for both conditions (about 38%), as was the average cell speed (5.7 versus 5.4 mm/min; not significant). We conclude that although there were small differences in the dynamics of antigen-specific T cell-DC interactions in tolerance and immunity, the trend of early arrest and slow recovery over 18 h was similar. costimulation 41, 42 . We conclude that a prolonged period of transient interactions is not necessary for the formation of stable conjugates between T cells and DCs. Potential explanations for the differences in the length of phase 1 in our study versus previous studies include the use in the latter of exogenously administered DCs that must migrate to the lymph node and enter the T cell area before presenting antigen 7 .
DISCUSSION
Another possibility is that T cells integrate signals during phase 1 encounters with DCs. In this model, antigen presented by many DCs after DEC-205 targeting 43, 44 might rapidly produce an integrated signal of the same magnitude as that obtained by T cells interacting with much less frequent immigrant DCs for over 8 h. Although further experimentation is needed to test these possibilities, it is presumably likely that the number of antigen-positive DCs will vary depending on how antigen reaches the lymph node. For example, soluble antigen rapidly drains to the lymph nodes and is widely accessible to resident lymph node DCs 45 . In addition, self antigens from dead cells and serum proteins are continually picked up, processed and presented by large numbers of resident DCs in the steady state. Thus, it seems likely that in conditions of immunity or tolerance, T cells can encounter varying numbers of antigen-bearing DCs and the kinetics of the initial T cell-DC interaction will depend on the relative frequency of antigen-positive DCs.
Imaging of T cell priming in explanted lymph nodes has shown clustering of antigen-specific T cells around DCs in the deep paracortex 3, 6 . We rarely noted formation of discrete T cell-DC clusters, but this was expected, as large numbers of DEC-205 + DCs in the lymph node present antigen after targeting with a-DEC-OVA 23, 30 and the number of T cells in each cluster is inversely proportional to the number of antigen-presenting DCs 3 . In our experiments, arrested antigen-specific T cells were not always in contact with CD11c hi DCs, which is consistent with the partial overlap between EYFP and DEC-205 expression in CD11c-EYFP mice 10 .
We found that the early stages of tolerance and immunity were similar in terms of T cell arrest near HEVs at 1-6 h, followed by resumed movement and dispersion in the deep paracortex by 18 and 24 h, respectively. The only difference we noted was that return to rapid migration was slower in conditions of priming than in conditions of tolerance. Our imaging results were consistent with our finding that T cell activation markers were identical and proliferation and responses to antigen in vitro were similar in the first 3 d of priming and tolerance induction. These experiments are also in agreement with physiological studies showing that T cells activated by soluble peptide in vivo are not committed to tolerance after 3 d (refs. [31] [32] [33] . Our results differ from those of a published two-photon study of tolerogenic T cell-DC interactions that used the same antigen delivery method (a-DEC-OVA) 6 . That study reported that CD8 + T cells arrest exclusively in priming and not in tolerance 6 . However, those experiments used explanted lymph nodes in which DCs were labeled by direct lymph node injection of antibody to CD11c and nonspecific T cells were not simultaneously imaged 6 . Our use of intravital microscopy preserved blood and lymph flow, whereas these physiological processes were lacking in the explanted lymph nodes used before 6 .
What is the importance of the prolonged T cell-DC interactions early in immune responses? Our experiments suggest that these conjugates are antigen specific but are not associated with commitment to immunity or tolerance and are independent of the state of DC maturation. We speculate that stable contacts between DCs and T cells are an integral part of initial T cell activation in vivo and that commitment to immunity or tolerance occurs later as T cells dynamically contact DCs.
METHODS
Transgenic mice. CD11c-EYFP mice, which have been described 10 , express EYFP-Venus under the control of the CD11c promoter and show bright fluorescence specifically in DCs. EGFP-OT-II mice were products of a cross between OT-II mice and mice ubiquitously expressing EGFP on the b-actin promoter 46, 47 ; ECFP mice express ECFP on the b-actin promoter 48 and were purchased from Jackson Labs. All strains used were fully backcrossed to a C57BL/6 background. Mice were used for experiments at the age of 4-6 weeks; all mice were housed in specific pathogen-free conditions and were treated in accordance with Institutional Animal Care and Use Committee protocols of Rockefeller University and New York University (New York, New York).
Immunofluorescence. Lymph nodes were fixed in PBS with 4% paraformaldehyde plus 10% sucrose and were cryoprotected in PBS plus 30% sucrose before being embedded in optimum cutting temperature compound and being frozen. Frozen tissue was sectioned on a microtome and was fixed in acetone. All incubations were done in a humidified chamber. Sections were blocked in 5% BSA and 10% serum in PBS in the presence of antibody to CD16 and CD32 (BD Biosciences) and were sequentially blocked with excess streptavidin and biotin (Vector Labs). The antibodies used were as follows: directly labeled antibody to CD3e-Alexa 647, antibody to B220-Alexa 647 (CalTag), biotinylated antibody to rat IgM, and unconjugated MECA-79 (BD Biosciences). Streptavidin-indocarbocyanine was from Jackson ImmunoResearch. Sections were mounted in Fluoromount-G (Southern Biotech) and were stored at 4 1C.
Confocal microscopy. Confocal images were acquired on a Zeiss LSM 510 system with 405-, 488-, 543-and 633-nm excitation lines; EGFP and ECFP fluorescence were visualized directly in all images. Optical sections were 1.2 mm for channels recording antibody staining and 5 mm in the channels recording EGFP. An array of images was obtained with a 40Â objective and a motorized stage to capture the entire cut surface of the lymph node, and images were exported into Adobe Photoshop for final processing. Positions of T cells, HEVs and the deep paracortex were measured with Volocity software (Improvision). Cells were assigned a score as being in the deep paracortex only if the entire cell was within the boundary; cells touching the boundary were excluded. The minimum distance from T cells to HEVs was calculated as described 37 with the following equation:
, where 'i' and 'j' are indices from '1yn' for T cells and HEVs, respectively, and 'min' is the minimum function. This yields the distance to the center of the HEV, which is greater than the distance to the basal side of the HEV endothelium.
Recombinant antibodies. For the production of a-DEC-OVA and the antibody to DEC-205 fused to the irrelevant peptide SYVPSAEQI, the sequence encoding hen egg lysozyme peptide in a-DEC-HEL 23 was replaced by molecular cloning. OVA peptide fused to an isotype control antibody was prepared as described 23 . Recombinant antibodies were produced by transient transfection and were purified as described 23 .
Antigen delivery and cell transfer. CD11c-EYFP mice were injected intraperitoneally with 2 mg of a-DEC-OVA, OVA peptide fused to an isotype control antibody, or irrelevant peptide targeted to DEC-205, either alone or together with a-CD40 (50 mg of clone 1C10). Then, 5 h later, mice were injected intravenously with 1 Â 10 7 to 2 Â 10 7 purified EGFP-OT-II T cells and naive CD4 + ECFP-T cells (purity greater than 98%) prepared by magnetic depletion of non-CD4 + T cells (MACS CD4 + T cell Kit; Miltenyi Biotec). Lymph nodes were imaged 2-18 h after T cell transfer ( Supplementary Fig. 2 online) . To examine HEVs in vivo, we injected 10 mg of Alexa 594-labeled MECA-79 antibody intravenously.
Transgenic T cell responses. OT-II T cells (CD45.2) were labeled with carboxyfluorescein diacetate succinimidyl diester (CFSE) and were transferred into 4-to 6-week-old B6/SJL mice and challenged intraperitoneally 24 h later with 2 mg a-DEC-OVA, 2 mg OVA peptide fused to an isotype control antibody, or PBS, or with 2 mg a-DEC-OVA plus 90 mg a-CD40. T cells were purified from peripheral lymph nodes 3 d or 7 d later and were cultured with irradiated CD11c + cells and OVA peptide to measure proliferation or were analyzed by flow cytometry on a FACSCalibur (BD Pharmingen) to measure CFSE dye dilution (gated on V a 2 and CD45.2). For monitoring of early T cell activation, 7 1 2 VOLUME 6 NUMBER 7 JULY 2005 NATURE IMMUNOLOGY CD45.2 OT-II T cells were transferred into CD45.1 B6/SJL mice injected 5 h before with a-DEC-OVA (with or without a-CD40); T cells were purified from lymph nodes at 3, 12 or 24 h after T cell transfer and were analyzed by flow cytometry to measure surface expression of CD69 and CD62L (gated on V a 2 and CD45.2). Antibodies were from BD Pharmingen.
Surgery. Mice were anesthetized with 100 mg ketamine, 15 mg xylazine and 2.5 mg acepromazine per kg and were kept anesthetized with hourly injections of half this dose. Mice were restrained on a stage warmer at 37 1C (BioTherm Micro S37; Biogenics) and the abdominal skin was incised from the edge of the rib cage through the midline to the thigh. A skin flap was separated from the abdominal muscle to expose the inguinal lymph node. To stabilize, moisturize and maintain the lymph node at 37 1C, we placed the skin flap on a thermoconductive base made of silicone elastomer (Sylgard 184; Dow Corning) surrounding a core of thermoconductive putty (T-putty 502; Thermagon). The connective and adipose tissue covering the lymph node was removed by microsurgery, keeping blood and lymph vessels intact, and a salinefilled chamber consisting of a coverslip glued to a nylon washer was mounted on the skin flap over the lymph node. The chamber was laterally secured by three insect pins piercing the skin and lodged in the silicone base. Temperature was monitored with a probe (Bioptechs) placed near the lymph node to ensure that it was at 37 7 1 1C. To compensate for anesthesia-induced respiratory depression, we provided mice with 100% oxygen by mask throughput the imaging session.
Intravital microscopy. The lymph node was imaged with a Bio-Rad Radiance multiphoton microscope fitted with a Tsunami pulsed laser (Spectraphysics) and controlled by Lasersharp2000 software (Bio-Rad). We used a Nikon 40Â objective (water immersed; numerical aperture, 0.8). For imaging of EYFP, EGFP and ECFP, the excitation wavelength was set to 910 nm. Band-pass filters optimized for detection of EYFP (550/30) and ECFP (510/30) and a 530 longpass dichroic mirror were used for detection of fluorescent proteins, with EGFP bright in both channels. Polyethylene glycol-coated 'quantum dots' (Qtracker 655; Quantum Dot) were injected with the same excitation for visualization of blood flow. To create time-lapse sequences, we typically scanned 50-Â 400-Â 400-mm volumes of tissue at 3-mm Z-steps and 30-second intervals.
Data analysis. Cell movement was analyzed with Volocity software (Improvision). For calculation of cell speeds, the coordinates of each cell were calculated and tracked over time and motility parameters were calculated. Average cell velocity was calculated as described 10 . Cells were characterized as immobile if their average velocity was less than 2 mm/min. The arrest coefficient was calculated as the percentage of each track in which the cell moved more slowly than 2 mm/min (ref. 6) . The turning angle is the absolute angle between the velocity vectors before and after a measurement time point 7 . The confinement index is calculated as the ratio of maximum displacement to path length 6 . Multivariate ANOVA was used to assess statistical significance and planned contrasts were used to assess differences between individual conditions when appropriate. P values less than 0.05 were considered significant.
Note: Supplementary information is available on the Nature Immunology website.
